Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-9 (Canceled)

10. (Withdrawn) A co-crystal comprising gabapentin and urea.

11. (Withdrawn) The co-crystal of claim 10, wherein

(a) the co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein:

(i) said co-crystal is a gabapentin:urea co-crystal and said X-ray diffraction pattern comprises peaks at 7.87, 16.97, and 22.25 degrees;

(ii) said co-crystal is a gabapentin:urea co-crystal and said X-ray diffraction pattern comprises peaks at 16.97, 24.61, and 29.33 degrees;

(iii) said co-crystal is a gabapentin:urea co-crystal and said X-ray diffraction pattern comprises peaks at 7.87, 24.61, and 29.33 degrees;

(iv) said co-crystal is a gabapentin:urea co-crystal and said X-ray diffraction pattern comprises peaks at 7.87 and 16.97 degrees;

(v) said co-crystal is a gabapentin:urea co-crystal and said X-ray diffraction pattern comprises peaks at 16.97 and 22.25 degrees;

(vi) said co-crystal is a gabapentin:urea co-crystal and said X-ray diffraction pattern comprises peaks at 7.87 and 22.25 degrees;

(vii) said co-crystal is a gabapentin:urea co-crystal and said X-ray diffraction pattern comprises a peak at 7.87 degrees;

(viii) said co-crystal is a gabapentin:urea co-crystal and said X-ray diffraction pattern comprises a peak at 16.97 degrees; or

(ix) said co-crystal is a gabapentin:urea co-crystal and said X-ray diffraction pattern comprises a peak at 22.25 degrees;

(b) the co-crystal is characterized by a DSC thermogram, wherein said DSC thermogram comprises an endothermic transition at about 171 degrees C.; or

(c) the co-crystal is characterized by a TGA thermogram, wherein said TGA thermogram comprises a weight loss of about 7.8 percent between about room temperature and about 88 degrees C.

12. (Withdrawn) A process for the preparation of a tartaric acid, ethanedisulfonic acid, or maleic acid salt of gabapentin, which comprises:

(1) mixing gabapentin with an organic acid to form a mixture;

(2) subjecting the mixture to conditions which salify the gabapentin whereby crystals of a gabapentin salt are formed; and

(3) optionally isolating the salt, wherein the organic acid is tartaric acid, ethanedisulfonic acid, or maleic acid.

13. (Withdrawn) The process according to claim 12, wherein the gabapentin is mixed with the organic acid in solution.

14. (Withdrawn) The process according to claim 13, wherein the mixture is subjected in step (2) to conditions to evaporate solvent.

15. (Withdrawn) The process according to claim 14, wherein step (2) further comprises heating and cooling the solution.

16. (Withdrawn) The process according to claim 12, wherein the gabapentin is mixed with the organic acid in a solid phase.

17. (Withdrawn) The process according to claim 16, wherein the mixture is a solid mixture which is subjected in step (2) to heating to salify the gabapentin.

18. (Withdrawn) The process according to claim 17, wherein the mixture is ground prior to heating.

19. (Withdrawn) A process for modulating the solubility of gabapentin for use in a pharmaceutical composition, which process comprises:

(1) mixing gabapentin with an organic acid to form a mixture; and

(2) salifying the gabapentin with the organic acid so that the solubility of the gabapentin is modulated, wherein the organic acid is tartaric acid, ethanedisulfonic acid, or maleic acid.

20. (Withdrawn) A process for modulating the dose response of gabapentin for use in a pharmaceutical composition, which process comprises:

(1) mixing gabapentin with an organic acid to form a mixture, and

(2) salifying the gabapentin with the organic acid so that the dose response of the gabapentin is modulated, wherein the organic acid is tartaric acid, ethanedisulfonic acid, or maleic acid.

21. (Withdrawn) A method for treating a subject with a brain disorder, which comprises administering to the subject a therapeutically effective amount of a tartaric acid, ethanedisulfonic acid, or maleic acid salt of gabapentin.

22. (Previously presented) An organic acid salt of gabapentin, wherein the organic acid is tartaric acid.

23. (Previously presented) The organic acid salt according to claim 22, wherein the organic acid is tartaric acid and the mole ratio of gabapentin to tartaric acid is approximately 1:1.

24. (Previously presented) The organic acid salt according to claim 22, wherein the salt is crystalline.

25. (Previously presented) The organic acid salt according to claim 22, wherein the salt is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, and said X-ray diffraction pattern comprises peaks at 5.1, 13.67, 16.91, 18.57, 19.55, and 21.57.

26. (Previously presented) The organic acid salt according to claim 22, wherein the salt is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, and said X-ray diffraction pattern comprises peaks at 5.1, 18.57, and 19.55.

27. (Previously presented) The organic acid salt according to claim 22, wherein the salt is characterized by a DSC thermogram, and said DSC thermogram comprises an endothermic transition at about 148 degrees C.

28. (Previously presented) The organic acid salt according to claim 22, wherein the salt is characterized by a TGA thermogram, and said TGA thermogram comprises a weight loss of about 11.5 percent between room temperature and about 175 degrees C.

29. (Currently amended) The organic acid salt according to claim 22, wherein the salt exhibits ~~a~~ single crystal X-ray crystallographic ~~analysis with crystal~~ parameters that are approximately equal to the following:

Unit cell parameters	
a (Å)	17.695(2)
b (Å)	6.6547(8)
c (Å)	13.3782(16)
α (°)	90
β (°)	107.317(2)
γ (°)	90
V (Å^3)	1503.9(3)

Z	4
Crystal system	Monoclinic
Space group	P2(1)/c
Density (Mg/m^3)	1.419
R1	0.0706
wR2	0.1553

30. (Currently amended) A pharmaceutical composition comprising ~~a tartaric acid salt of gabapentin.~~the organic acid salt of claim 22.

31. (Previously presented) The pharmaceutical composition according to claim 30, which further comprises a pharmaceutically acceptable carrier, diluent, or excipient.

32. (Previously presented) An organic acid salt of gabapentin, wherein the organic acid is ethanedisulfonic acid.

33. (Previously presented) The organic acid salt according to claim 32, wherein the organic acid is ethanedisulfonic acid and the mole ratio of gabapentin to ethanedisulfonic acid is approximately 2:1.

34. (Previously presented) The organic acid salt according to claim 32, wherein the salt is crystalline.

35. (Previously presented) The organic acid salt according to claim 32, wherein the salt is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, and said X-ray diffraction pattern comprises peaks at 6.17, 11.49, 15.05, 17.35, 20.21, and 24.65.

36. (Previously presented) The organic acid salt according to claim 32, wherein the salt is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, and said X-ray diffraction pattern comprises peaks at 6.17, 17.35, and 20.21.

37. (Previously presented) The organic acid salt according to claim 32, wherein the salt is characterized by a DSC thermogram, and said DSC thermogram comprises an endothermic transition at about 184 degrees C.

38. (Previously presented) The organic acid salt according to claim 32, wherein the salt is characterized by a TGA thermogram, and said TGA thermogram comprises a weight loss of about 38 percent between about 100 degrees C and about 263 degrees C.

39. (Currently amended) The organic acid salt according to claim 32, wherein the salt exhibits ~~a~~ single crystal X-ray crystallographic ~~analysis with crystal~~ parameters that are approximately equal to the following:

Unit cell parameters	
a (Å)	5.5971 (7)
b (Å)	8.0151 (10)
c (Å)	14.6776 (18)
α (°)	78.971 (2)
β (°)	88.025 (2)
γ (°)	75.867 (2)
V ($Å^3$)	626.68 (13)
Z	2
Crystal system	Triclinic
Space group	P(-1)
Density (Mg/m^3)	1.411
R1	0.0632
wR2	0.1446

40. (Currently amended) A pharmaceutical composition comprising ~~an ethanedisulfonic acid salt of gabapentin~~ the organic acid salt of claim 32.

41. (Previously presented) The pharmaceutical composition according to claim 40, which further comprises a pharmaceutically acceptable carrier, diluent, or excipient.

42. (Previously presented) An organic acid salt of gabapentin, wherein the organic acid is maleic acid.

43. (Previously presented) The organic acid salt according to claim 42, wherein the salt is crystalline.

44. (Previously presented) The organic acid salt according to claim 42, wherein the salt is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, and said X-ray diffraction pattern comprises peaks at 4.6, 6.7, 7.8, 14.99, 16.93, 20.47, and 28.03.

45. (Previously presented) The organic acid salt according to claim 42, wherein the salt is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, and said X-ray diffraction pattern comprises peaks at 4.6, 6.7, and 7.8.

46. (Previously presented) The organic acid salt according to claim 42, wherein the salt is characterized by a DSC thermogram, and said DSC thermogram comprises an endothermic transition at about 71 degrees C.

47. (Previously presented) The organic acid salt according to claim 42, wherein the salt is characterized by a DSC thermogram, and said DSC thermogram comprises an endothermic transition at about 102 degrees C.

48. (Currently amended) A pharmaceutical composition comprising ~~a maleic acid salt of gabapentin~~ the organic acid salt of claim 42.

49. (Previously presented) The pharmaceutical composition according to claim 48, which further comprises a pharmaceutically acceptable carrier, diluent, or excipient.